Antiviral drugs and the treatment of hepatitis C.
Curr HIV/AIDS Rep
; 9(2): 132-8, 2012 Jun.
Article
em En
| MEDLINE
| ID: mdl-22354528
ABSTRACT
With effective treatment of HIV-1, hepatitis C virus (HCV) has become increasingly recognized as a major cause of morbidity and mortality in this population. Rapid progression of liver disease and cirrhosis has been documented in HIV/HCV co-infected individuals, particularly with lower CD4-counts (< 200/µL). Therefore, HCV treatment has become a priority for many clinicians, despite the presence of many. An important issue among HIV/HCV co-infected patients is the selection of antiretroviral therapy (ART) during treatment with pegylated interferon, ribavirin (RBV), plus new HCV protease inhibitors. Extensive drug-drug interactions (DDI) and overlapping drug-associated adverse events can impact the outcome of HCV therapy. In this review, we focus on the important data and studies regarding optimizing antiretroviral regimens before starting HCV treatment in HIV/HCV co-infected patients to increase the chance of sustained virologic response (SVR).
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Infecções por HIV
/
Hepatite C
/
Inibidores Enzimáticos
Limite:
Humans
Idioma:
En
Revista:
AIDS Rep
Assunto da revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Estados Unidos